Structural implications for selective targeting of PARPs

Frontiers in Oncology

Volumn 3 DEC, Issue , 2013, Pages

  Steffen, Jamin D ^a   Brody, Jonathan R ^b   Armen, Roger S ^b   Pascal, John M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Inhibitor design; PARP; Selectivity; Structure

Indexed keywords

BYK 204165; DR 2313; FR 257517; ME 0328; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; REV PROTEIN; RUCAPARIB; UNCLASSIFIED DRUG; VELIPARIB;

CANCER CHEMOTHERAPY; CELL FATE; CELL FUNCTION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DNA DAMAGE; DNA REPAIR; DRUG POTENCY; HUMAN; IC 50; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

EID: 84892384683     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00301     Document Type: Review

References (90)

1. Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci (2010) 35:208-19. doi: 10.1016/j.tibs.2009.12.003.
2. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays (2004) 26:882-93. doi:10.1002/bies.20085.
3. Steffen JD, Pascal JM. New players to the field of ADP-ribosylation make the final cut. EMBO J (2013) 32:1205-7. doi:10.1038/emboj.2013.83.
4. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res (2005) 52:25-33. doi:10.1016/j.phrs.2005.02.010.
5. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434:913-7. doi:10.1038/nature03443.
6. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434:917-21. doi:10.1038/nature03445.
7. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol (2008) 26:3785-90. doi:10.1200/JCO.2008.16.0812.
8. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, MacChiarulo A, Thorsell A, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol (2012) 30:283-8. doi:10.1038/nbt.2121.
9. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science (1998) 282:1484-7. doi:10.1126/science.282.5393.1484.
10. Liu Y, Snow BE, Kickhoefer VA, Erdmann N, Zhou W, Wakeham A, et al. Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo. Mol Cell Biol (2004) 24:5314-23. doi:10.1128/MCB.24.12.5314-5323.2004.
11. Langelier MF, Planck JL, Roy S, Pascal JM. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science (2012) 336:728-32. doi:10.1126/science.1216338.
12. Bell CE, Eisenberg D. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry (1996) 35:1137-49. doi:10.1021/bi9520848.
13. Ruf A, de Murcia G, Schulz GE. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry (1998) 37:3893-900. doi:10.1021/bi972383s.
14. Rolli V, O'Farrell M, Ménissier-de Murcia J, de Murcia G. Random mutagenesis of the poly(ADP-ribose) polymerase catalytic domain reveals amino acids involved in polymer branching. Biochemistry (1997) 36:12147-54. doi:10.1021/bi971055p.
15. Ruf A, Rolli V, de Murcia G, Schulz GE. The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. J Mol Biol (1998) 278:57-65. doi:10.1006/jmbi.1998.1673.
16. Langelier MF, Pascal JM. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol (2013) 23:134-43. doi:10.1016/j.sbi.2013.01.003.
17. Cohen-Armon M, Visochek L, Rozensal D, Kalal A, Geistrikh I, Klein R, et al. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell (2007) 25:297-308. doi:10.1016/j.molcel.2006.12.012.
18. Lehtiö L, Collins R, van den Berg S, Johansson A, Dahlgren LG, Hammarstrom M, et al. Zinc binding catalytic domain of human tankyrase 1. J Mol Biol (2008) 379:136-45. doi:10.1016/j.jmb.2008.03.058.
19. Lehtiö L, Jemth A, Collins R, Loseva O, Johansson A, Markova N, et al. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem (2009) 52:3108-11. doi:10.1021/jm900052j.
20. Loseva O, Jemth AS, Bryant HE, Schuler H, Lehtio L, Karlberg T, et al. PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA. J Biol Chem (2010) 285:8054-60. doi:10.1074/jbc.M109.077834.
21. Rulten SL, Fisher AE, Robert I, Zuma MC, Rouleau M, Ju L, et al. PARP-3 and APLF function together to accelerate nonhomologous end-joining. Mol Cell (2011) 41:33-45. doi:10.1016/j.molcel.2010.12.006.
22. Oliver AW, Ame JC, Roe SM, Good V, de Murcia G, Pearl LH. Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. Nucleic Acids Res (2004) 32:456-64. doi:10.1093/nar/gkh215.
23. Langelier MF, Planck JL, Roy S, Pascal JM. Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity. J Biol Chem (2011) 286:10690-701. doi:10.1074/jbc.M110.202507.
24. Langelier MF, Ruhl DD, Planck JL, Kraus WL, Pascal JM. The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction. J Biol Chem (2010) 285:18877-87. doi:10.1074/jbc.M110.105668.
25. Loeffler P, Cuneo M, Mueller G, DeRose E, Gabel S, London R. Structural studies of the PARP-1 BRCT domain. BMC Struct Biol (2011) 11:37. doi:10.1186/1472-6807-11-37.
26. Kickhoefer VA, Siva AC, Kedersha NL, Inman EM, Ruland C, Streuli M, et al. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol (1999) 146:917-28. doi:10.1083/jcb.146.5.917.
27. Sbodio JI, Chi NW. Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1. NuMA contains this RXXPDG motif and is a novel tankyrase partner. J Biol Chem (2002) 277:31887-92. doi:10.1074/jbc.M203916200.
28. Morrone S, Cheng Z, Moon RT, Cong F, Xu W. Crystal structure of a tankyrase-axin complex and its implications for axin turnover and tankyrase substrate recruitment. Proc Natl Acad Sci U S A (2012) 109:1500-5. doi:10.1073/pnas.1116618109.
29. Guettler S, LaRose J, Petsalaki E, Gish G, Scotter A, Pawson T, et al. Structural basis and sequence rules for substrate recognition by tankyrase explain the basis for Cherubism disease. Cell (2011) 147:1340-54. doi:10.1016/j.cell.2011.10.046.
30. Lyons RJ, Deane R, Lynch DK, Ye ZS, Sanderson GM, Eyre HJ, et al. Identification of a novel human tankyrase through its interaction with the adaptor protein Grb14. J Biol Chem (2001) 276:17172-80. doi:10.1074/jbc.M009756200.
31. Durkacz BW, Irwin J, Shall S. Inhibition of (ADP-ribose)n biosynthesis retards DNA repair but does not inhibit DNA repair synthesis. Biochem Biophys Res Commun (1981) 101:1433-41. doi:10.1016/0006-291X(81)91607-7.
32. Banasik M, Komura H, Shimoyama M, Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem (1992) 267:1569-75.
33. Rankin PW, Jacobson EL, Benjamin RC, Moss J, Jacobson MK. Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J Biol Chem (1989) 264:4312-7.
34. Ruf A, Mennissier de Murcia J, de Murcia G, Schulz GE. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc Natl Acad Sci U S A (1996) 93:7481-5. doi:10.1073/pnas.93.15.7481.
35. Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem (2010) 53:4561-84. doi:10.1021/jm100012m.
36. Ame JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, et al. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem (1999) 274:17860-8. doi:10.1074/jbc.274.25.17860.
37. Perkins E, Sun D, Nguyen A, Tulac S, Francesco M, Tavana H, et al. Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast. Cancer Res (2001) 61:4175-83.
38. Kinoshita T, Nakanishi I, Warizaya M, Iwashita A, Kido Y, Hattori K, et al. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Lett (2004) 556:43-6. doi:10.1016/S0014-5793(03)01362-0.
39. Iwashita A, Hattori K, Yamamoto H, Ishida J, Kido Y, Kamijo K, et al. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett (2005) 579:1389-93. doi:10.1016/j.febslet.2005.01.036.
40. Ishida J, Yamamoto H, Kido Y, Kamijo K, Murano K, Miyake H, et al. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling. Bioorg Med Chem (2006) 14:1378-90. doi:10.1016/j.bmc.2005.09.061.
41. Eltze T, Boer R, Wagner T, Weinbrenner S, McDonald MC, Thiemermann C, et al. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol Pharmacol (2008) 74:1587-98. doi:10.1124/mol.108.048751.
42. Karlberg T, Hammarstrom M, Schutz P, Svensson L, Schuler H. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry (2010) 49:1056-8. doi:10.1021/bi902079y.
43. Huang SA, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature (2009) 461:614-20. doi:10.1038/nature08356.
44. Pellicciari R, Camaioni E, Costantino G, Formentini L, Sabbatini P, Venturoni F, et al. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives. ChemMedChem (2008) 3:914-23. doi:10.1002/cmdc.200800010.
45. Lindgren AE, Karlberg T, Thorsell AG, Hesse M, Spjut S, Ekblad T, et al. PARP inhibitor with selectivity toward ADP-ribosyltransferase ARTD3/PARP3. ACS Chem Biol (2013) 8:1698-703. doi:10.1021/cb4002014.
46. Kirby CA, Cheung A, Fazal A, Shultz MD, Stams T. Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 68:115-8. doi:10.1107/S1744309111051219.
47. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan C, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol (2009) 5:100-7. doi:10.1038/nchembio.137.
48. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res (2012) 72:2822-32. doi:10.1158/0008-5472.CAN-11-3336.
49. Yashiroda Y, Okamoto R, Hatsugai K, Takemoto Y, Goshima N, Saito T, et al. A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor. Biochem Biophys Res Commun (2010) 394:569-73. doi:10.1016/j.bbrc.2010.03.021.
50. Narwal M, Venkannagari H, Lehtio L. Structural basis of selective inhibition of human tankyrases. J Med Chem (2012) 55:1360-7. doi:10.1021/jm201510p.
51. Gunaydin H, Gu Y, Huang X. Novel binding mode of a potent and selective tankyrase inhibitor. PLoS One (2012) 7(3):e33740. doi:10.1371/journal.pone.0033740.
52. Shultz MD, Kirby CA, Stams T, Chin DN, Blank J, Charlat O, et al. [1,2,4]-(triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J Med Chem (2012) 55:1127-36. doi:10.1021/jm2011222.
53. Karlberg T, Markova N, Johansson I, Hammarstrom M, Schutz P, Weigelt J, et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J Med Chem (2010) 53:5352-5. doi:10.1021/jm100249w.
54. Bregman H, Chakka N, Guzman-Perez A, Gunaydin H, Gu Y, Huang X, et al. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. J Med Chem (2013) 56:4320-42. doi:10.1021/jm4000038.
55. Bregman H, Gunaydin H, Gu Y, Schneider S, Wilson C, DiMauro EF, et al. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. J Med Chem (2013) 56:1341-5. doi:10.1021/jm301607v.
56. Kirsten E, Kun E. Cancer cell selectivity of 5-iodo-6-aminobenzopyrone (INH2BP) and methyl-3,5-diiodo-4(4'-methoxyphenoxy)benzoate (DIME). Int J Mol Med (2000) 5:279-81.
57. Buki KG, Bauer PI, Mendeleyev J, Hakam A, Kun E. Inactivation of the polymerase but not the dna binding function of ADPRT by destabilization of one of its Zn2+ coordination centers by 6-nitroso-1,2-benzopyrone. In: Poirier GG, Moreau P, editors. ADP-Ribosylation Reactions. New York: Springer (1992). p. 329-33.
58. Mendeleyev J, Kirsten E, Hakam A, Buki KG, Kun E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Biochem Pharmacol (1995) 50:705-14. doi:10.1016/0006-2952(95)00189-7.
59. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med (2011) 364:205-14. doi:10.1056/NEJMoa1011418.
60. Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res (2012) 18:510-23. doi:10.1158/1078-0432.CCR-11-1973.
61. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res (2012) 18:1655-62. doi:10.1158/1078-0432.CCR-11-2890.
62. Steffen JD, Tholey R, Planck JL, Langelier MF, Schiewer MJ, Bildzukewicz NA, et al. Targeting PARP-1 allosteric regulation holds promising therapeutic potential in treating cancer. Cancer Res (2013). doi:10.1158/0008-5472.CAN-13-1701.
63. Zerbe BS, Hall DR, Vajda S, Whitty A, Kozakov D. Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces. J Chem Inf Model (2012) 52:2236-44. doi:10.1021/ci300175u.
64. Lee MS, Feig M, Salsbury FR Jr, Brooks CL III. New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations. J Comput Chem (2003) 24:1348-56. doi:10.1002/jcc.10272.
65. Rahaman O, Estrada TP, Doren DJ, Taufer M, Brooks CL III, Armen RS. Evaluation of several two-step scoring functions based on linear interaction energy, effective ligand size, and empirical pair potentials for prediction of protein-ligand binding geometry and free energy. J Chem Inf Model (2011) 51:2047-65. doi:10.1021/ci1003009.
66. Chapman JD, Gagné JP, Poirier GG, Goodlett DR. Mapping PARP-1 auto-ADP-ribosylation sites by liquid chromatography-tandem mass spectrometry. J Proteome Res (2013) 12:1868-80. doi:10.1021/pr301219h.
67. Altmeyer M, Messner S, Hassa PO, Fey M, Hottiger MO. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res (2009) 37:3723-38. doi:10.1093/nar/gkp229.
68. Messner S, Altmeyer M, Zhao H, Pozivil A, Roschitzki B, Gehrig P, et al. PARP1 ADP-ribosylates lysine residues of the core histone tails. Nucleic Acids Res (2010) 38:6350-62. doi:10.1093/nar/gkq463.
69. Ogata N, Ueda K, Kagamiyama H, Hayaishi O. ADP-ribosylation of histone H1. Identification of glutamic acid residues 2, 14, and the COOH-terminal lysine residue as modification sites. J Biol Chem (1980) 255:7616-20.
70. Sharifi R, Morra R, Appel CD, Tallis M, Chioza B, Jankevicius G, et al. Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease. EMBO J (2013) 32:1225-37. doi:10.1038/emboj.2013.51.
71. De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol (2012) 84:137-46. doi:10.1016/j.bcp.2012.03.018.
72. Ström CE, Johansson F, Uhlén M, Szigyarto CA, Erixon K, Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res (2011) 39:3166-75. doi:10.1093/nar/gkq1241.
73. Satoh MS, Poirier GG, Lindahl T. Dual function for poly(ADP-ribose) synthesis in response to DNA strand breakage. Biochemistry (1994) 33:7099-106. doi:10.1021/bi00189a012.
74. Molinete M, Vermeulen W, Burkle A, Menissier-de Murcia J, Kupper JH, Hoeijmakers JH, et al. Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells. EMBO J (1993) 12:2109-17.
75. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res (2012) 72:5588-99. doi:10.1158/0008-5472.CAN-12-2753.
76. Montoni A, Robu M, Pouliot E, Shah GM. Resistance to PARP-inhibitors in cancer therapy. Front Pharmacol (2013) 4:18. doi:10.3389/fphar.2013.00018.
77. Pishvaian MJ, Slack R, Witkiewicz A, He AR, Hwang JJ, Hankin A, et al. A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer. J Clin Oncol (2011) 29.
78. Van Der Heijden MS, Brody JR, Kern SE. Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot. Cancer Biol Ther (2004) 3:534-7. doi:10.4161/cbt.3.6.844.
79. Burkhart RA, Peng Y, Norris ZA, Tholey R, Talbott VA, Liang Q, et al. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Mol Cancer Res (2013) 11:901-11. doi:10.1158/1541-7786.MCR-12-0699.
80. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther (2009) 8:2992-3000. doi:10.1158/1535-7163.MCT-09-0463.
81. Nakajima H, Kakui N, Ohkuma K, Ishikawa M, Hasegawa T. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J Pharmacol Exp Ther (2005) 312:472-81. doi:10.1124/jpet.104.075465.
82. Zhang J, Lautar S, Huang S, Ramsey C, Cheung A, Li JH. GPI 6150 prevents H2O2 cytotoxicity by inhibiting poly(ADP-ribose) polymerase. Biochem Biophys Res Commun (2000) 278:590-8. doi:10.1006/bbrc.2000.3816.
83. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. ClustalW and ClustalX version 2. Bioinformatics (2007) 23(21):2947-8. doi:10.1093/bioinformatics/btm404.
84. Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview version 2: a multiple sequence alignment and analysis workbench. Bioinformatics (2009) 25:1189-91. doi:10.1093/bioinformatics/btp033.
85. Sunderland PT, Woon ECY, Dhami A, Bergin AB, Mahon MF, Wood PJ, et al. 5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2). J Med Chem (2011) 54:2049-59. doi:10.1021/jm1010918.
86. Menear KA, Adcock C, Boulter R, Cockcroft X, Copsey L, Cranston A, et al. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem (2008) 51:6581-91. doi:10.1021/jm8001263.
87. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, et al. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem (2009) 52:514-23. doi:10.1021/jm801171j.
88. Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, et al. Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors. J Med Chem (2009) 52:7170-85. doi:10.1021/jm901188v.
89. Torrisi C, Bisbocci M, Ingenito R, Ontoria JM, Rowley M, Schultz-Fademrecht C, et al. Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett (2009) 20:448-52. doi:10.1016/j.bmcl.2009.12.002.
90. Larsson EA, Jansson E, Ng FM, Then SW, Panicker R, Liu B, et al. Fragment-based ligand design of novel potent inhibitors of tankyrases. J Med Chem (2013) 56:4497-508. doi:10.1021/jm400211f.